Your browser doesn't support javascript.
loading
Tumors recycle glucocorticoids to drive Treg-mediated immunosuppression.
Swatler, Julian; Ju, Young-Jun; Anderson, Ana C; Lugli, Enrico.
Afiliação
  • Swatler J; Laboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan.
  • Ju YJ; Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Anderson AC; Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Lugli E; Laboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan.
J Clin Invest ; 133(18)2023 09 15.
Article em En | MEDLINE | ID: mdl-37712416
ABSTRACT
Suppression of antitumor immunity is a prominent feature of the tumor microenvironment. In this issue of the JCI, Taves, Otsuka, and authors show that glucocorticoids (GCs), which are potent immunosuppressive hormones mainly produced by the adrenals, can be reconverted from their inactive form to active metabolites via the 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) enzyme expressed by murine tumor cell lines. In the tumor microenvironment, GCs acted on CD4+ regulatory T cells to enhance their immunosuppressive function and promote tumor growth. The findings suggest that targeting GC recycling as a strategy for modulating tumor immunosuppression has the potential to improve therapeutic efficacy of immune checkpoint blockade.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T Reguladores / Glucocorticoides Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T Reguladores / Glucocorticoides Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article